Method for inducing dopaminergic neuron progenitor cells
US-2016215260-A1 · Jul 28, 2016 · US
Method for inducing dopaminergic neuron progenitor cells
US12545894B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12545894-B2 |
| Application number | US-202217824603-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 25, 2022 |
| Priority date | Sep 5, 2013 |
| Publication date | Feb 10, 2026 |
| Grant date | Feb 10, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a method for producing dopaminergic neuron progenitor cells from pluripotent stem cells, which method comprises the steps of: (i) performing adherent culture of pluripotent stem cells on an extracellular matrix in a medium containing a reagent(s) selected from the group consisting of BMP inhibitor, TGFβ inhibitor, SHH signal-stimulating agent, FGF8, and GSK3β inhibitor; (ii) collecting Corin- and/or Lrtm1-positive cells from the cells obtained in Step (i) using a substance which binds to Corin and/or a substance which binds to Lrtm1; and (iii) performing suspension culture of the cells obtained in Step (ii) in a medium containing a neurotrophic factor.
First claim
Opening claim text (preview).
What is claimed is: 1 . A method of treating Parkinson's disease, comprising steps: (1) preparing a cell aggregate comprising dopaminergic neuron progenitor cells, wherein Step (1) comprises: (i) culturing pluripotent stem cells on an extracellular matrix in a medium containing a reagent(s) selected from the group consisting of BMP inhibitor, TGFβ inhibitor, SHH signal-stimulating agent, FGF8, and GSK3β inhibitor during a period enough for appearance of Corin- and/or leucine-rich repeats and transmembrane domains 1 (Lrtm1) positive cells; (ii) collecting Corin- and/or Lrtm1-positive cells from the cells obtained in Step (i) using a substance which binds to Corin and/or a substance which binds to Lrtm1; and (iii) culturing the cells obtained in Step (ii) in suspension in a medium containing a neurotrophic factor, wherein Step (iii) is carried out for at least 7 days, and (2) transplanting the cell aggregate obtained by Step (1) into a brain of a patient suffering from Parkinson's disease.
Assignees
Inventors
Classifications
from non-embryonic pluripotent stem cells · CPC title
Neurons · CPC title
from artificially induced pluripotent stem cells · CPC title
from embryonic cells · CPC title
Kinases (EC 2.7.) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12545894B2 cover?
- The present invention provides a method for producing dopaminergic neuron progenitor cells from pluripotent stem cells, which method comprises the steps of: (i) performing adherent culture of pluripotent stem cells on an extracellular matrix in a medium containing a reagent(s) selected from the group consisting of BMP inhibitor, TGFβ inhibitor, SHH signal-stimulating agent, FGF8, and GSK3β inhi…
- Who is the assignee on this patent?
- Univ Kyoto, Univ Osaka, Eisai R&D Man Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K35/30. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 10 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).